目次

TABLE OF CONTENTS

1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE
1.3.2 INCLUSIONS AND EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS

2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Objectives of secondary research
2.1.1.2 Key data from secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Breakdown of primaries (supply- and demand-side participants)
2.1.2.2 Key objectives of primary research
2.2 MARKET SIZE ESTIMATION
2.2.1 GLOBAL MARKET SIZE ESTIMATION
2.2.1.1 Company revenue analysis (Bottom-up approach)
2.2.1.2 Revenue share analysis
2.2.1.3 MnM repository analysis
2.2.1.4 Primary interviews
2.2.2 INSIGHTS FROM PRIMARY EXPERTS
2.2.3 SEGMENTAL MARKET SIZE ESTIMATION (TOP-DOWN APPROACH)
2.3 GROWTH RATE PROJECTIONS
2.4 DATA TRIANGULATION
2.5 RESEARCH ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY
3.1 STRATEGIC IMPERATIVES FOR KEY STAKEHOLDERS
3.1.1 BIOTECH STARTUPS AND INNOVATIVE COMPANIES
3.1.2 ESTABLISHED MARKET LEADERS
3.1.3 CDMOS AND CROS

4 PREMIUM INSIGHTS
4.1 TARGETED PROTEIN DEGRADERS MARKET OVERVIEW
4.2 NORTH AMERICA: TARGETED PROTEIN DEGRADERS MARKET, BY DEGRADER TYPE AND COUNTRY, 2030
4.3 TARGETED PROTEIN DEGRADERS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
4.4 TARGETED PROTEIN DEGRADERS MARKET: EMERGING VS. DEVELOPED MARKETS

5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Growing approvals and favorable regulatory environment
5.2.1.2 Multi-indication expansion
5.2.1.3 Capital inflows and big pharma tie-ups
5.2.1.4 Technological advancements in design and discovery
5.2.2 RESTRAINTS
5.2.2.1 Cost and scalability issues
5.2.2.2 Safety-related concerns
5.2.2.3 Intellectual property disputes
5.2.3 OPPORTUNITIES
5.2.3.1 Advancements in medicinal chemistry
5.2.3.2 Development of next-gen ligases with tissue-selective expressions
5.2.3.3 Increasing NDA filings for innovative degraders
5.2.4 CHALLENGES
5.2.4.1 Limited ligase expression in tissues
5.2.4.2 Strict regulatory guidelines
5.3 TECHNOLOGY ANALYSIS
5.3.1 KEY TECHNOLOGIES
5.3.1.1 PROTACS (hetero-bifunctional)
5.3.1.2 Molecular glues/CELMODS
5.3.2 COMPLEMENTARY TECHNOLOGIES
5.3.2.1 Next-gen E3-ligase binder discovery
5.3.2.2 Nanoparticle/LNP delivery of degraders
5.3.3 ADJACENT TECHNOLOGIES
5.3.3.1 Antibody-drug conjugates (ADCs)
5.3.3.2 GENE editing/siRNA
5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESSES
5.5 PRICING ANALYSIS
5.5.1 QUALITATIVE PRICING INSIGHTS FOR ELACESTRANT (ORSERDU), 2024
5.5.2 QUALITATIVE PRICING INSIGHTS FOR UPCOMING NOVEL TARGETED PROTEIN DEGRADERS
5.6 REIMBURSEMENT SCENARIO FOR ELACESTRANT (ORSERDU)
5.6.1 US
5.6.2 EUROPE
5.7 VALUE CHAIN ANALYSIS
5.8 ECOSYSTEM ANALYSIS
5.9 PATENT ANALYSIS
5.10 PIPELINE ANALYSIS
5.11 REGULATORY ANALYSIS
5.11.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS, BY REGION
5.11.2 REGULATORY FRAMEWORK
5.12 KEY CONFERENCES AND EVENTS, 2025-2026
5.13 PORTER'S FIVE FORCES ANALYSIS
5.13.1 THREAT OF NEW ENTRANTS
5.13.2 THREAT OF SUBSTITUTES
5.13.3 BARGAINING POWER OF SUPPLIERS
5.13.4 BARGAINING POWER OF BUYERS
5.13.5 INTENSITY OF COMPETITIVE RIVALRY
5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.14.2 KEY BUYING CRITERIA
5.15 INVESTMENT AND FUNDING SCENARIO
5.16 IMPACT OF AI/GEN AI ON TARGETED PROTEIN DEGRADERS MARKET
5.17 IMPACT OF 2025 US TARIFFS ON TARGETED PROTEIN DEGRADERS MARKET
5.17.1 INTRODUCTION
5.17.2 KEY TARIFF RATES
5.17.3 PRICE IMPACT ANALYSIS
5.17.4 IMPACT ON COUNTRY/REGION
5.17.4.1 North America
5.17.4.1.1 US
5.17.4.2 Europe
5.17.4.3 Asia Pacific
5.17.5 IMPACT ON END-USE INDUSTRIES

6 TARGETED PROTEIN DEGRADERS MARKET, BY DEGRADER TYPE
6.1 INTRODUCTION
6.2 MOLECULAR GLUE
6.2.1 MEZIGDOMIDE (CC-92480)
6.2.1.1 Stronger cereblon binding and deeper substrate degradation to spur growth
6.2.2 IBERDOMIDE (CC-220)
6.2.2.1 Rising incidence of autoimmune diseases and cancer to boost market
6.3 SERDS
6.3.1 ELACESTRANT
6.3.1.1 Increasing approvals to contribute to growth
6.3.2 GIREDESTRANT (GDC9545)
6.3.2.1 Growing prevalence of breast cancer to drive market
6.3.3 CAMIZESTRANT (AZD9833)
6.3.3.1 High potency and strong receptor degradation to bolster growth
6.4 PROTAC
6.4.1 VEPDEGESTRANT (ARV-471)
6.4.1.1 Reliable systemic exposure and enhanced tumor targeting to support growth
6.4.2 LUXDEGALUTAMIDE
6.4.2.1 Favorable safety profile and early signals of efficacy to stimulate growth
6.4.3 BGB-16673
6.4.3.1 Higher efficacy and preference for oral formulation to aid growth
6.4.4 NX-5948
6.4.4.1 Advancements in next-gen oral BTK degraders targeting refractory B-cell malignancies to drive market
6.4.5 KT-474
6.4.5.1 Rising importance in treating autoimmune and inflammatory diseases to aid growth
6.5 LDD/BIDAC
6.5.1 INCREASING USE OF LDD IN TUMOR-SPECIFIC DEGRADATION, HEMATOLOGIC CANCERS, AND IMMUNE MODULATION TO FUEL MARKET
6.6 LYTAC/ATAC
6.6.1 GROWING FOCUS ON CANCER IMMUNOTHERAPY TO DRIVE MARKET
6.7 AUTAC/ATTEC
6.7.1 GROWING USE OF AUTAC IN TREATING METABOLIC DISEASES AND RARE LYSOSOMAL STORAGE CONDITIONS TO BOOST MARKET

7 TARGETED PROTEIN DEGRADERS MARKET, BY THERAPEUTIC INDICATION
7.1 INTRODUCTION
7.2 ONCOLOGY
7.2.1 HIGH PREVALENCE OF MALIGNANCIES AND UNMET NEED FOR DURABLE THERAPIES TO PROMOTE GROWTH
7.3 INFLAMMATORY DISEASES
7.3.1 CHANGES IN LIFESTYLES AND ENVIRONMENTAL CONDITIONS TO AUGMENT GROWTH
7.4 OTHER DISEASES

8 TARGETED PROTEIN DEGRADERS MARKET, BY FORMULATION
8.1 INTRODUCTION
8.2 ORAL FORMULATIONS
8.2.1 TABLETS
8.2.1.1 Manufacturing scalability, stability, and patient convenience to aid growth
8.2.2 CAPSULES
8.2.2.1 Higher flexibility, faster development timelines, and enhanced bioavailability to foster growth
8.3 INJECTIONS
8.3.1 ESSENTIAL ROLE IN RAPID AND TARGETED DELIVERY OF SYSTEMIC TARGETED PROTEIN DEGRADERS TO BOOST MARKET

9 TARGETED PROTEIN DEGRADERS MARKET, BY END USER
9.1 INTRODUCTION
9.2 HOSPITALS & SPECIALTY CLINICS
9.2.1 ROBUST INFRASTRUCTURE AND MULTI-DISCIPLINARY CARE TEAMS TO EXPEDITE GROWTH
9.3 LONG-TERM CARE FACILITIES
9.3.1 INCREASING FOCUS ON QUALITY OF LIFE TO CONTRIBUTE TO GROWTH
9.4 HOME CARE SETTINGS
9.4.1 GROWING FOCUS ON CHRONIC DISEASE MANAGEMENT TO DRIVE MARKET

10 TARGETED PROTEIN DEGRADERS MARKET, BY REGION
10.1 INTRODUCTION
10.2 NORTH AMERICA
10.2.1 MACROECONOMIC ANALYSIS FOR NORTH AMERICA
10.2.2 US
10.2.2.1 Strong clinical pipeline and regulatory support to contribute to growth
10.2.3 CANADA
10.2.3.1 Favorable government initiatives to support growth
10.3 EUROPE
10.3.1 MACROECONOMIC ANALYSIS FOR EUROPE
10.3.2 GERMANY
10.3.2.1 Strong industry-academia partnership to foster growth
10.3.3 UK
10.3.3.1 Presence of leading academic institutions and translational research hubs to aid growth
10.3.4 FRANCE
10.3.4.1 Presence of leading biotechnology and diagnostic companies to spur growth
10.3.5 ITALY
10.3.5.1 Increasing innovations in PROTAC technology to promote growth
10.3.6 SPAIN
10.3.6.1 Robust academic network to contribute to growth
10.3.7 REST OF EUROPE
10.4 ASIA PACIFIC
10.4.1 MACROECONOMIC ANALYSIS FOR ASIA PACIFIC
10.4.2 CHINA
10.4.2.1 Surge in clinical trial activities to spur growth
10.4.3 JAPAN
10.4.3.1 Large geriatric population to contribute to growth
10.4.4 INDIA
10.4.4.1 Expanding contract development and manufacturing organization infrastructure to fuel market
10.4.5 SOUTH KOREA
10.4.5.1 Rapidly expanding pharmaceutical manufacturing infrastructure to propel market
10.4.6 AUSTRALIA
10.4.6.1 Streamlined clinical trial environment to accelerate growth
10.4.7 REST OF ASIA PACIFIC
10.5 LATIN AMERICA
10.5.1 MACROECONOMIC ANALYSIS FOR LATIN AMERICA
10.5.2 BRAZIL
10.5.2.1 Regulatory evolution supporting trial acceleration to drive market
10.5.3 MEXICO
10.5.3.1 Rising demand for novel therapeutics for chronic disease treatment to support growth
10.5.4 REST OF LATIN AMERICA
10.6 MIDDLE EAST & AFRICA
10.6.1 MACROECONOMIC ANALYSIS FOR MIDDLE EAST & AFRICA
10.6.2 GCC COUNTRIES
10.6.2.1 Saudi Arabia
10.6.2.1.1 Growing focus on life sciences sector to boost market
10.6.2.2 UAE
10.6.2.2.1 Emerging biotechnology sector to intensify growth
10.6.2.3 REST OF GCC countries
10.6.3 REST OF MIDDLE EAST & AFRICA

11 COMPETITIVE LANDSCAPE
11.1 INTRODUCTION
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN TARGETED PROTEIN DEGRADERS MARKET
11.3 REVENUE ANALYSIS, 2028-2030
11.4 MARKET SHARE ANALYSIS, 2030
11.5 COMPANY VALUATION AND FINANCIAL METRICS
11.5.1 COMPANY VALUATION
11.5.2 FINANCIAL METRICS
11.6 BRAND/PRODUCT COMPARISON
11.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
11.7.1 STARS
11.7.2 EMERGING LEADERS
11.7.3 PERVASIVE PLAYERS
11.7.4 PARTICIPANTS
11.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
11.7.5.1 Company footprint
11.7.5.2 Region footprint
11.7.5.3 Degrader type footprint
11.7.5.4 Therapeutic indication footprint
11.7.5.5 Formulation footprint
11.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
11.8.1 PROGRESSIVE COMPANIES
11.8.2 RESPONSIVE COMPANIES
11.8.3 DYNAMIC COMPANIES
11.8.4 STARTING BLOCKS
11.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
11.8.5.1 Detailed list of key startups/SMEs
11.8.5.2 Competitive benchmarking of key startups/SMEs
11.9 COMPETITIVE SCENARIO
11.9.1 PRODUCT LAUNCHES AND APPROVALS
11.9.2 DEALS
11.9.3 EXPANSIONS

12 COMPANY PROFILES
12.1 KEY PLAYERS
12.1.1 BRYSTOL-MYERS SQUIBB COMPANY
12.1.1.1 Business overview
12.1.1.2 Products offered
12.1.1.3 Recent developments
12.1.1.3.1 Deals
12.1.1.3.2 Expansions
12.1.1.4 MnM view
12.1.1.4.1 Key strengths
12.1.1.4.2 Strategic choices
12.1.1.4.3 Weaknesses and competitive threats
12.1.2 THE MENARINI GROUP
12.1.2.1 Business overview
12.1.2.2 Products offered
12.1.2.3 Recent developments
12.1.2.3.1 Product launches and approvals
12.1.2.4 MnM view
12.1.2.4.1 Key strengths
12.1.2.4.2 Strategic choices
12.1.2.4.3 Weaknesses and competitive threats
12.1.3 ARVINAS
12.1.3.1 Business overview
12.1.3.2 Products offered
12.1.3.3 Recent developments
12.1.3.3.1 Deals
12.1.3.4 MnM view
12.1.3.4.1 Key strengths
12.1.3.4.2 Strategic choices
12.1.3.4.3 Weaknesses and competitive threats
12.1.4 BEONE MEDICINES
12.1.4.1 Business overview
12.1.4.2 Products offered
12.1.4.3 Recent developments
12.1.4.3.1 Deals
12.1.5 NURIX THERAPEUTICS, INC.
12.1.5.1 Business overview
12.1.5.2 Products offered
12.1.5.3 Recent developments
12.1.5.3.1 Deals
12.1.6 KYMERA THERAPEUTICS, INC.
12.1.6.1 Business overview
12.1.6.2 Products offered
12.1.6.3 Recent developments
12.1.6.3.1 Deals
12.1.7 C4 THERAPEUTICS, INC.
12.1.7.1 Business overview
12.1.7.2 Products offered
12.1.7.3 Recent developments
12.1.7.3.1 Deals
12.1.8 ASTRAZENECA
12.1.8.1 Business overview
12.1.8.2 Products offered
12.1.8.3 Recent developments
12.1.8.3.1 Deals
12.1.8.3.2 Expansions
12.1.9 F. HOFFMANN-LA ROCHE LTD
12.1.9.1 Business overview
12.1.9.2 Products offered
12.1.9.3 Recent developments
12.1.9.3.1 Deals
12.1.10 BAYER AG
12.1.10.1 Business overview
12.1.10.2 Products offered
12.1.10.3 Recent developments
12.1.10.3.1 Deals
12.1.11 CAPTOR THERAPEUTICS
12.1.11.1 Business overview
12.1.11.2 Products offered
12.1.11.3 Recent developments
12.1.11.3.1 Deals
12.1.12 RANOK THERAPEUTICS CO. LTD.
12.1.12.1 Business overview
12.1.12.2 Products offered
12.1.12.3 Recent developments
12.1.12.3.1 Product launches and approvals
12.1.13 PFIZER INC.
12.1.13.1 Business overview
12.1.13.2 Products offered
12.1.13.3 Recent developments
12.1.13.3.1 Product launches and approvals
12.1.14 NOVARTIS AG
12.1.14.1 Business overview
12.1.14.2 Products offered
12.1.14.3 Recent developments
12.1.14.3.1 Deals
12.1.15 FOGHORN THERAPEUTICS
12.1.15.1 Business overview
12.1.15.2 Products offered
12.1.15.3 Recent developments
12.1.15.3.1 Deals
12.2 OTHER PLAYERS
12.2.1 MONTE ROSA THERAPEUTICS
12.2.2 BIOTHERYX, INC.
12.2.3 CULLGEN
12.2.4 NEOMORPH
12.2.5 LYCIA THERAPEUTICS
12.2.6 PHOTYS THERAPEUTICS
12.2.7 PLEXIUM, INC.
12.2.8 SEED THERAPEUTICS, INC.
12.2.9 AVILAR THERAPEUTICS, INC.
12.2.10 AUTOMERA

13 APPENDIX
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
13.3 CUSTOMIZATION OPTIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS